Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer drug help heal chronic brain bleeds without surgery?

NCT ID NCT07729098

Disease control Sponsor: Dheeraj Gandhi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This early-stage trial tests whether adding a single dose of the drug bevacizumab directly into the brain's lining artery can improve the standard minimally invasive procedure for chronic subdural hematoma — a slow brain bleed common in older adults. Up to 18 adults who are already scheduled for middle meningeal artery embolization will receive the drug during the same procedure. The main goal is to check safety and find the best dose, while also tracking whether the bleed shrinks more than with embolization alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bevacizumab (Avastin) given directly into the artery of the brain lining
What this could lead to
If safe and effective, this combination approach could offer a less invasive way to treat chronic subdural hematoma and reduce the need for surgical drainage.
What could go wrong
This is a very early phase 1 trial with only 18 participants, so safety and dosing are still being explored. Bevacizumab carries risks of bleeding and impaired wound healing, especially when given into a brain artery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-85 years * Scheduled to undergo MMAE as standard of care for cSDH, no concurrent surgical evacuation planned (prior surgery for the target cSDH allowed if ≥14 days elapsed) * Radiographically confirmed cSDH meeting specified unilateral/bilateral density criteria * cSDH volume 20-100 cc * Midline shift \<8 mm * Markwalder Grade 1 or 2 * Subject or LAR able to provide written informed consent Exclusion Criteria: * Requires immediate/urgent surgical evacuation * Prior large craniotomy, membranectomy, or MMAE for the current target cSDH * Life expectancy \<1 year * Uncontrolled bleeding disorder (INR \>1.7, aPTT \>35s, platelets \<100,000/μL) * Concurrent intracranial hemorrhage outside the target subdural space * Persistent neurological deficit from another acute/chronic neurological condition * Pregnancy or lactation * Known/suspected intracranial neoplasm or mass lesion * Active alcohol/substance use disorder within 12 months * Baseline mRS ≥3 * Uncontrolled severe hypertension (SBP \>220 or DBP \>120, or IV antihypertensive need within 24h pre-procedure) * Thromboembolic event within 6 months (DVT, PE, TIA, stroke) * Contraindication to VTE prophylaxis * eGFR \<60 mL/min/1.73m² or acute kidney injury at screening * Known hypersensitivity to bevacizumab or its components

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic subdural hematoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hematoma, Subdural, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic subdural hematoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.